2 Risky, 2 Safe Pharma Plays
The following video is part of our "Motley Fool Conversations" series, in which advisor James Early and senior technology analyst Eric Bleeker discuss topics across the investing world.
In today's edition, James takes a look at the pharma world and keys in on a phrase that should strike fear into any pharma investor's heart: the dreaded "patent cliff." He's particularly weary that AstraZeneca and Eli Lilly, two companies that face looming patent cliffs, might look to ill-conceived deals in coming years. James recommends that pharma investors instead look to both Johnson & Johnson and GlaxoSmithKline.
One of the best reasons to invest in pharma is the solid dividends paid out by the companies. For example, James' recommendation in this video, as well as those in this report: "Secure Your Future With 11 Rock-Solid Dividend Stocks." You can access your complimentary copy today at no cost! Just click here to discover the winners we've picked.
At the time this article was published Eric Bleeker has no positions in the stocks mentioned above. James Early owns shares of Johnson & Johnson. The Motley Fool owns shares of AstraZeneca, GlaxoSmithKline, and Johnson & Johnson.Motley Fool newsletter services recommendGlaxoSmithKline and Johnson & Johnson. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.